The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).

Chihiro Kosugi,Hirohiko Kamiyama,Yoichiro Yoshida,Hiroshi Yoshida,Keiichiro Ishibashi,Keisuke Ihara,Makoto Takahashi,Hidekazu Kuramochi,Hiromichi Sonoda,Kazuhiko Yoshimatsu,Atsuko Fukazawa,Akihisa Matsuda,Satoru Yamaguchi,Hideyuki Ishida,Suguru Hasegawa,Takeshi Yamada,Kazuo Narushima,Kiyohiko Shuto,Kazuhiro Sakamoto,Keiji Koda

The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).

2019

614Background: TAS-102 improved overall survival of metastatic colorectal cancer (mCRC) patients with median progression free survival (PFS) of 2.0 months (RECOURSE trial). Subsequently, the combin...

Keywords:

Bevacizumab
Progression-free survival
Oncology
Pathology
Colorectal cancer
Chemotherapy
Internal medicine
Medicine
third line chemotherapy
overall survival

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations